Literature DB >> 1899274

Clinical applications of carbon dioxide/digital subtraction arteriography.

F A Weaver1, M J Pentecost, A E Yellin, S Davis, E Finck, G Teitelbaum.   

Abstract

During an 18-month period 33 patients in whom there were contraindications to the use of iodinated contrast arteriography underwent 40 carbon dioxide/digital subtraction arteriograms for lower extremity ischemia (19), severe hypertension and renal insufficiency (12), or arterial aneurysm (2). Contraindications to iodinated contrast agents included renal insufficiency, congestive heart failure, and contrast hypersensitivity. Sixteen aortic, 15 iliac-femoral-popliteal-tibial, five aorta-iliac-femoral and four aorta-iliac-femoral-popliteal-tibial carbon dioxide/digital subtraction arteriography studies were performed. In 11 studies, imaging of selected arterial segments required the addition of 10 to 60 ml of dilute nonionic contrast. Guided by carbon dioxide/digital subtraction arteriography studies four femoral-tibial bypasses, three aneurysmorrhaphies, two aortorenal bypasses, one aortofemoral bypass and one femoral-femoral bypass were successfully performed in 11 patients. In addition, carbon dioxide/digital subtraction arteriography directed angioplasties of the common iliac (4), superficial femoral (6), popliteal (3), or tibioperoneal trunk (1) were performed in 10 patients. Complications of carbon dioxide/digital subtraction arteriography included transient deterioration in renal function in three patients in whom 20 ml of nonionic contrast was used, a nonfatal myocardial infarction after a popliteal percutaneous transluminal angioplasty in one patient, and transient tachypnea and tachycardia during a carbon dioxide/digital subtraction arteriography study in one patient. Diagnostic arteriograms are obtainable using carbon dioxide as the contrast agent. Carbon dioxide/digital subtraction arteriography permits patients with symptomatic arterial disease at high risk for contrast related complications to safely undergo arteriography and subsequent arterial reconstruction or endovascular intervention.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899274

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

1.  CO(2) wedged hepatic venography in the evaluation of portal hypertension.

Authors:  W Debernardi-Venon; J C Bandi; J C García-Pagán; E Moitinho; V Andreu; M Real; A Escorsell; X Montanyá; J Bosch
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

2.  Carbon dioxide gas as a venous contrast agent to guide upper-arm insertion of central venous catheters.

Authors:  S T Hahn; T Pfammatter; K J Cho
Journal:  Cardiovasc Intervent Radiol       Date:  1995 May-Jun       Impact factor: 2.740

3.  Venography with carbon dioxide as a contrast agent.

Authors:  K L Sullivan; J Bonn; M J Shapiro; G A Gardiner
Journal:  Cardiovasc Intervent Radiol       Date:  1995 May-Jun       Impact factor: 2.740

4.  CO2 spray mini-injector for digital subtraction angiography versus PC-controlled injection system: experiments in dogs.

Authors:  T Schmitz-Rode; G Alzen; R W Günther; H Pott
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Sep-Oct       Impact factor: 2.740

5.  Carbon dioxide gas as an arterial contrast agent.

Authors:  J M Seeger; S Self; T R Harward; T C Flynn; I F Hawkins
Journal:  Ann Surg       Date:  1993-06       Impact factor: 12.969

6.  Medical Grand Rounds: refractory hypertension and renal insufficiency in a patient with renal artery stenosis.

Authors:  S J Huot; L M Scoutt; G H Meier
Journal:  Yale J Biol Med       Date:  1996 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.